ProCE Banner Activity

Beyond CDK4/6 Inhibition: Putting New Data on Targeting the PI3K Pathway Into Clinical Practice

Slideset Download
Download this slideset to review the latest clinical data on the evolving role of mTOR and PIK3 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Released: December 11, 2019

Expiration: December 09, 2020

Share

Faculty

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Immunomedics

Lilly

Faculty Disclosure

Primary Author

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California